Clinical Trials Browser

Phase 2 × Crizotinib × Lymphoid × Clear all

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04439266 2026-05-07

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Phase 2 Active not recruiting

5 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06360575 2026-05-04

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Phase 2 Active not recruiting

20 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04439253 2026-04-29

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Phase 2 Active not recruiting

4 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06357975 2026-03-19

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Phase 2 Active not recruiting

44 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01979536 2024-04-30

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase 2 Completed

137 enrolled 13 charts

Lymphoma, Large-Cell, Anaplastic

NCT01524926 2023-12-11

CREATE

Phase 2 Completed

LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

NCT02419287 2023-03-06

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Phase 2 Completed

Lymphoma, Large-Cell, Anaplastic

NCT02435108 2017-02-17

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

Phase 2 Completed

Lymphoma, Follicular